Summary

Eligibility
for people ages 18-90 (full criteria)
Location
at UCSF
Dates
study started
completion around

Description

Summary

There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This study aims to characterize the impact of palliative care versus biopsy versus resection on survival and quality of life in these patients. Also, it will aim to determine if there is a subset of patients that benefit the most from resection or biopsy, for which outcome, and how they could be identified preoperatively.

This study is an international, multicenter, prospective, 3-arm cohort study of observational nature. Consecutive HGG patients will be treated with palliative care, biopsy, or resection at a 1:3:3 ratio. Primary endpoints are: 1) overall survival, and 2) quality of life at 6 weeks, 3 months and 6 months after initial presentation based on the EQ-5D, EORTC QLQ C30 and EORTC BN 20 questionnaires. Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.

Details

Keywords

Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme, Adult, Palliative care, Best supportive care, Biopsy, Resection, Quality of life, Survival, Tumor biopsy, Tumor resection

Eligibility

Locations

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States
  • Massachusetts General Hospital accepting new patients
    Boston Massachusetts 02114 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Jasper Gerritsen
ID
NCT06146738
Study Type
Observational
Participants
Expecting 1015 study participants
Last Updated